Peregrine Pharma (PPHM) Reports In-Line Q2 Loss

Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) reported Q2 loss of ($0.15), in-line with the analyst estimate of ($0.15). Revenue for the quarter came in at $2.83 million versus the consensus estimate of $2.28 million.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
• ATRenew Inc (RERE) Tops Q2 EPS by 8c ; Offers Guidance
• ZKH Group Limited (ZKH) Reports Q2 EPS of $0.04